NCT05638178
Completed
Not Applicable
The Middle Norway Corona Study - Individual and Genetic Risk Factors for COVID-19 Infection.
St. Olavs Hospital5 sites in 1 country223 target enrollmentStarted: May 1, 2020Last updated:
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- St. Olavs Hospital
- Enrollment
- 223
- Locations
- 5
- Primary Endpoint
- Predictors of COVID-19 severity
Overview
Brief Summary
CUT COVID is a cohort study establised to collect information on patients hospitalized because or with infection by SARS-CoV-2. The cohort data includes clinical data and biological samples from multiple timepoints during hospitalization, as well as data from a followup consultation 3 months after discharge.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Positive SARS CoV-2 infection
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Predictors of COVID-19 severity
Time Frame: 1 year after inclusion.
Primary aim is to assess predictors of severe COVID disease in children and adults
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (5)
Loading locations...
Similar Trials
Unknown
Not Applicable
Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19SARS VirusSevere Acute Respiratory SyndromeNCT04381819Oslo University Hospital1,000
Completed
Not Applicable
Clinical Course and Treatment of COVID-19 Inpatients in HospitalCOVID-19NCT04527497Wissenschaftliches Institut Bethanien e.V35
Completed
Not Applicable
COVID-19 Community Research PartnershipCoronavirusCOVIDNCT04342884Wake Forest University Health Sciences61,410
Completed
Not Applicable
The NOR-COR Study for Coronary PreventionSecondary Coronary PreventionNCT02309255Vestre Viken Hospital Trust975
Completed
Not Applicable
An Observational Study of Patients With Coronavirus Disease 2019COVID-19CoronavirusNCT04331886Target PharmaSolutions, Inc.199